Advertisement

Inflammation Research

, Volume 68, Issue 3, pp 203–213 | Cite as

Immunological modulation following bone marrow-derived mesenchymal stromal cells and Th17 lymphocyte co-cultures

  • Mehdi Najar
  • Hussein Fayyad-Kazan
  • Wissam H. FaourEmail author
  • Makram Merimi
  • Etienne M. Sokal
  • Catherine A. Lombard
  • Hassan Fahmi
Original Research Paper

Abstract

Objective and design

The objective of the study is to uncover the influence of human bone marrow-derived mesenchymal stem cells (BM-MSCs) on the generation of Th17 lymphocytes in co-cultures of both BM-MSCs and T cells.

Materials and methods

BM-MSCs, characterized according to the international society for cellular therapy (ISCT) criteria, were co-cultured with T cells isolated from peripheral blood. The expression levels of IL-17 receptor, RORγt and IL-23 receptor were evaluated using flow cytometry. The levels of cytokines involved in Th17 immunomodulation were measured using multiplex assay.

Treatment

Inflammatory primed and non-primed BM-MSCs were co-cultured with either activated or non-activated T cells either at (1/80) and (1/5) ratio respectively.

Results

MSC/T-cell ratio and inflammation significantly influenced the effect of BM-MSCs on the generation of Th17 lymphocytes. Cocultures of either primed or non-primed BM-MSCs with activated T cells significantly induced IL-17A-expressing lymphocytes. Interestingly, the expression of the transcription factor RORγt was significantly increased when compared to levels in activated T cells. Finally, both cell ratio and priming of BM-MSCs with cytokines substantially influenced the cytokine profile of BM-MSCs and T cells.

Conclusion

Our findings suggest that BM-MSCs significantly modulate the Th17 lymphocyte pathway in a complex manner.

Keywords

Th17 Cytokines ROR-γt MSCs T cells IL-23R Co-culture 

Notes

Acknowledgements

The authors thank Laurence Lagneaux for providing preparations of MSCs and Fatema Bouhtit for her technical assistance. The authors would like to also thank Noureddine Boukhatem for his helpful discussions. This project was supported by “Le Fonds National de la Recherche Scientifique, F.R.S.-FNRS”, the “Télévie” and the Canadian Institutes of Health Research (Grant MOP-130293). Furthermore, we would like to thank Bio-Rad Laboratories, Inc. for technical support during the study.

Author contributions

All authors contributed to this work, all authors participated in the writing and drafting of the manuscript as well as critically reviewing it. WF, MN and HFK did the statistical analysis. WF, MN and HFK significantly contributed to the writing process. All authors read and agreed with the final format of the manuscript.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This study was conducted in accordance with the Declaration of Helsinki (1964) and the protocol and experiments were approved by the local ethics committee of the “Institut Jules Bordet” (Belgium).

References

  1. 1.
    Zaher W, Harkness L, Jafari A, Kassem M. An update of human mesenchymal stem cell biology and their clinical uses. Arch Toxicol. 2014;88:1069–82.CrossRefGoogle Scholar
  2. 2.
    Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315–7.CrossRefGoogle Scholar
  3. 3.
    Wang Y, Chen X, Cao W, Shi Y. Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications. Nat Immunol. 2014;15:1009–16.CrossRefGoogle Scholar
  4. 4.
    Najar M, Raicevic G, Fayyad-Kazan H, Bron D, Toungouz M, Lagneaux L. Mesenchymal stromal cells and immunomodulation: a gathering of regulatory immune cells. Cytotherapy. 2016;18:160–71.CrossRefGoogle Scholar
  5. 5.
    Michael S, Achilleos C, Panayiotou T, Strati K. Inflammation shapes stem cells and stemness during infection and beyond. Front Cell Dev Biol. 2016;4:118.CrossRefGoogle Scholar
  6. 6.
    Noack M, Miossec P. Th17 and regulatory T cell balance in autoimmune and inflammatory diseases. Autoimmun Rev. 2014;13:668–77.CrossRefGoogle Scholar
  7. 7.
    Iwakura Y, Ishigame H. The IL-23/IL-17 axis in inflammation. J Clin Investig. 2006;116:1218–22.CrossRefGoogle Scholar
  8. 8.
    Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell. 2006;126:1121–33.CrossRefGoogle Scholar
  9. 9.
    Bouffi C, Bony C, Courties G, Jorgensen C, Noel D. IL-6-dependent PGE2 secretion by mesenchymal stem cells inhibits local inflammation in experimental arthritis. PLoS One. 2010;5:e14247.CrossRefGoogle Scholar
  10. 10.
    Najar M, Raicevic G, Fayyad-Kazan H, De Bruyn C, Bron D, Toungouz M, et al. Immune-related antigens, surface molecules and regulatory factors in human-derived mesenchymal stromal cells: the expression and impact of inflammatory priming. Stem Cell Rev. 2012;8:1188–98.CrossRefGoogle Scholar
  11. 11.
    Najar M, Fayyad-Kazan H, Faour WH, Badran B, Journe F, Lagneaux L. Breast cancer cells and bone marrow mesenchymal stromal cells: a regulated modulation of the breast tumor in the context of immune response. Inflamm Res. 2017;66:129–39.CrossRefGoogle Scholar
  12. 12.
    Najar M, Rouas R, Raicevic G, Boufker HI, Lewalle P, Meuleman N, et al. Mesenchymal stromal cells promote or suppress the proliferation of T lymphocytes from cord blood and peripheral blood: the importance of low cell ratio and role of interleukin-6. Cytotherapy. 2009;11:570–83.CrossRefGoogle Scholar
  13. 13.
    Zhou L, Ivanov II, Spolski R, Min R, Shenderov K, Egawa T, et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol. 2007;8:967–74.CrossRefGoogle Scholar
  14. 14.
    Mangan PR, Harrington LE, O’Quinn DB, Helms WS, Bullard DC, Elson CO, et al. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature. 2006;441:231–4.CrossRefGoogle Scholar
  15. 15.
    van Kooten C, Gaillard C, Galizzi JP, Hermann P, Fossiez F, Banchereau J, et al. B cells regulate expression of CD40 ligand on activated T cells by lowering the mRNA level and through the release of soluble CD40. Eur J Immunol. 1994;24:787–92.CrossRefGoogle Scholar
  16. 16.
    Gao F, Chiu SM, Motan DA, Zhang Z, Chen L, Ji HL, et al. Mesenchymal stem cells and immunomodulation: current status and future prospects. Cell Death Dis. 2016;7:e2062.CrossRefGoogle Scholar
  17. 17.
    Ma OK, Chan KH. Immunomodulation by mesenchymal stem cells: interplay between mesenchymal stem cells and regulatory lymphocytes. World J Stem Cells. 2016;8:268–78.CrossRefGoogle Scholar
  18. 18.
    Tso GH, Law HK, Tu W, Chan GC, Lau YL. Phagocytosis of apoptotic cells modulates mesenchymal stem cells osteogenic differentiation to enhance IL-17 and RANKL expression on CD4+ T cells. Stem Cells. 2010;28:939–54.Google Scholar
  19. 19.
    Lai K, Zeng K, Zeng F, Wei J, Tan G. Allogeneic adipose-derived stem cells suppress Th17 lymphocytes in patients with active lupus in vitro. Acta Biochim Biophys Sin (Shanghai). 2011;43:805–12.CrossRefGoogle Scholar
  20. 20.
    Darlington PJ, Boivin MN, Renoux C, Francois M, Galipeau J, Freedman MS, et al. Reciprocal Th1 and Th17 regulation by mesenchymal stem cells: implication for multiple sclerosis. Ann Neurol. 2010;68:540–5.CrossRefGoogle Scholar
  21. 21.
    Farahani R, Sherkat R, Hakemi MG, Eskandari N, Yazdani R. Cytokines (interleukin-9, IL-17, IL-22, IL-25 and IL-33) and asthma. Adv Biomed Res. 2014;3:127.CrossRefGoogle Scholar
  22. 22.
    Ivanov II, Zhou L, Littman DR. Transcriptional regulation of Th17 cell differentiation. Semin Immunol. 2007;19(6):409–17.CrossRefGoogle Scholar
  23. 23.
    Miossec P. Update on interleukin-17: a role in the pathogenesis of inflammatory arthritis and implication for clinical practice. RMD Open. 2017;3:e000284.CrossRefGoogle Scholar
  24. 24.
    Guo Z, Zheng C, Chen Z, Gu D, Du W, Ge J, et al. Fetal BM-derived mesenchymal stem cells promote the expansion of human Th17 cells, but inhibit the production of Th1 cells. Eur J Immunol. 2009;39:2840–9.CrossRefGoogle Scholar
  25. 25.
    Cho MR. Targeting interleukin-17 and Th17 in immune inflammatory diseases. Hanyang Med Rev. 2013;33:17–26.CrossRefGoogle Scholar
  26. 26.
    Glenn JD, Whartenby KA. Mesenchymal stem cells: emerging mechanisms of immunomodulation and therapy. World J Stem Cells. 2014;6:526–39.CrossRefGoogle Scholar
  27. 27.
    Chen B, Hu J, Liao L, Sun Z, Han Q, Song Z, et al. Flk-1+ mesenchymal stem cells aggravate collagen-induced arthritis by up-regulating interleukin-6. Clin Exp Immunol. 2010;159:292–302.CrossRefGoogle Scholar
  28. 28.
    Svobodova E, Krulova M, Zajicova A, Pokorna K, Prochazkova J, Trosan P, et al. The role of mouse mesenchymal stem cells in differentiation of naive T-cells into anti-inflammatory regulatory T-cell or proinflammatory helper T-cell 17 population. Stem Cells Dev. 2012;21:901–10.CrossRefGoogle Scholar
  29. 29.
    Senhaji N, Kojok K, Darif Y, Fadainia C, Zaid Y. The contribution of CD40/CD40L axis in inflammatory bowel disease: an update. Front Immunol. 2015;6:529.CrossRefGoogle Scholar
  30. 30.
    Zheng Y, Sun L, Jiang T, Zhang D, He D, Nie H. TNFalpha promotes Th17 cell differentiation through IL-6 and IL-1beta produced by monocytes in rheumatoid arthritis. J Immunol Res 2014; 2014:385352.Google Scholar
  31. 31.
    Ke F, Zhang L, Liu Z, Yan S, Xu Z, Bai J, Zhu H, Lou F, Cai W, Sun Y, Gao Y, Wang H, Wang H. Soluble tumor necrosis factor receptor 1 released by skin-derived mesenchymal stem cells is critical for inhibiting Th17 cell differentiation. Stem Cells Trans Med. 2016;5(3):301–13.CrossRefGoogle Scholar
  32. 32.
    Huber S, Gagliani N, Esplugues E, O’Connor W Jr, Huber FJ, Chaudhry A, et al. Th17 cells express interleukin-10 receptor and are controlled by Foxp3(−) and Foxp3+ regulatory CD4+ T cells in an interleukin-10-dependent manner. Immunity. 2011;34:554–65.CrossRefGoogle Scholar
  33. 33.
    Korn T, Bettelli E, Gao W, Awasthi A, Jager A, Strom TB, et al. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature. 2007;448:484–7.CrossRefGoogle Scholar
  34. 34.
    Nurieva R, Yang XO, Martinez G, Zhang Y, Panopoulos AD, Ma L, et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature. 2007;448:480–3.CrossRefGoogle Scholar
  35. 35.
    Murphy CA, Langrish CL, Chen Y, Blumenschein W, McClanahan T, Kastelein RA, et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med. 2003;198:1951–7.CrossRefGoogle Scholar
  36. 36.
    Sonnenberg GF, Fouser LA, Artis D. Functional biology of the IL-22-IL-22R pathway in regulating immunity and inflammation at barrier surfaces. Adv Immunol. 2010;107:1–29.CrossRefGoogle Scholar
  37. 37.
    Iwakura Y, Ishigame H, Saijo S, Nakae S. Functional specialization of interleukin-17 family members. Immunity. 2011;34:149–62.CrossRefGoogle Scholar
  38. 38.
    Wang WB, Yen ML, Liu KJ, Hsu PJ, Lin MH, Chen PM, et al. Interleukin-25 mediates transcriptional control of PD-L1 via STAT3 in multipotent human mesenchymal stromal cells (hMSCs) to suppress Th17 responses. Stem Cell Rep. 2015;5:392–404.CrossRefGoogle Scholar
  39. 39.
    Martin NT, Martin MU. Interleukin 33 is a guardian of barriers and a local alarmin. Nat Immunol. 2016;17:122–31.CrossRefGoogle Scholar
  40. 40.
    Zhang Q, Putheti P, Zhou Q, Liu Q, Gao W. Structures and biological functions of IL-31 and IL-31 receptors. Cytokine Growth Factor Rev. 2008;19:347–56.CrossRefGoogle Scholar
  41. 41.
    Stott B, Lavender P, Lehmann S, Pennino D, Durham S, Schmidt-Weber CB. Human IL-31 is induced by IL-4 and promotes TH2-driven inflammation. J Allergy Clin Immunol 2013; 132:446–54.e5.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  • Mehdi Najar
    • 1
  • Hussein Fayyad-Kazan
    • 2
  • Wissam H. Faour
    • 3
    Email author
  • Makram Merimi
    • 4
    • 5
  • Etienne M. Sokal
    • 6
  • Catherine A. Lombard
    • 6
  • Hassan Fahmi
    • 1
  1. 1.Osteoarthritis Research Unit, Department of MedicineUniversity of Montreal Hospital Research Center (CRCHUM)MontrealCanada
  2. 2.Laboratory of Cancer Biology and Molecular Immunology, Faculty of Sciences ILebanese UniversityHadathLebanon
  3. 3.Pharmacology, Gilbert and Rose-Mary Chagoury School of MedicineLebanese American UniversityByblosLebanon
  4. 4.Laboratory of Experimental Hematology, Jules Bordet InstituteUniversité Libre de BruxellesBrusselsBelgium
  5. 5.Laboratory of Physiology, Ethnopharmacology and Genetics, Faculty of SciencesUniversity Mohammed PremierOujdaMorocco
  6. 6.Laboratory of Pediatric Hepatology and Cell Therapy, Institut de Recherche Expérimentale and Clinique (IREC)Université Catholique de LouvainBrusselsBelgium

Personalised recommendations